Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years.
Standard
Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years. / Thoem, Ina; Rogers, Claudia; Andritzky, Birte; Witzel, Isabell; Schuch, Gunter; Hossfeld, Dieter Kurt; Bokemeyer, Carsten; Laack, Eckart.
in: ONKOLOGIE, Jahrgang 32, Nr. 12, 12, 2009, S. 741-746.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years.
AU - Thoem, Ina
AU - Rogers, Claudia
AU - Andritzky, Birte
AU - Witzel, Isabell
AU - Schuch, Gunter
AU - Hossfeld, Dieter Kurt
AU - Bokemeyer, Carsten
AU - Laack, Eckart
PY - 2009
Y1 - 2009
N2 - BACKGROUND: Cancer of unknown primary site (CUP syndrome) is a particular challenge in oncology which occurs in about 5-10% of cancer patients. Here, we investigated clinicopathological and prognostic factors in patients with CUP syndrome in a retrospective analysis. PATIENTS AND METHODS: 136 patients with CUP syndrome who were treated in our Department of Oncology and Hematology were analyzed over a period of 10 years. Clinical and histopathological characteristics, response to chemotherapy, survival and prognostic factors were investigated in a retrospective analysis. RESULTS: 83 of the patients (61%) received first-line chemotherapy, which induced an overall response rate of 19%. Altogether 37 different chemotherapy regimens were used. Median overall survival of all patients was 7.9 months. In multivariate Cox regression analysis, gender, Karnofsky performance status, treatment modality and extent of disease were identified as independent prognostic factors. CONCLUSIONS: Our analysis showed a poor prognosis for patients with CUP syndrome. The response rate to chemotherapy was low with no significant benefit for any of the investigated cytotoxic agents. Newer diagnostic and therapeutical approaches might contribute to an improvement of prognosis, and their value is currently investigated in prospective studies.
AB - BACKGROUND: Cancer of unknown primary site (CUP syndrome) is a particular challenge in oncology which occurs in about 5-10% of cancer patients. Here, we investigated clinicopathological and prognostic factors in patients with CUP syndrome in a retrospective analysis. PATIENTS AND METHODS: 136 patients with CUP syndrome who were treated in our Department of Oncology and Hematology were analyzed over a period of 10 years. Clinical and histopathological characteristics, response to chemotherapy, survival and prognostic factors were investigated in a retrospective analysis. RESULTS: 83 of the patients (61%) received first-line chemotherapy, which induced an overall response rate of 19%. Altogether 37 different chemotherapy regimens were used. Median overall survival of all patients was 7.9 months. In multivariate Cox regression analysis, gender, Karnofsky performance status, treatment modality and extent of disease were identified as independent prognostic factors. CONCLUSIONS: Our analysis showed a poor prognosis for patients with CUP syndrome. The response rate to chemotherapy was low with no significant benefit for any of the investigated cytotoxic agents. Newer diagnostic and therapeutical approaches might contribute to an improvement of prognosis, and their value is currently investigated in prospective studies.
M3 - SCORING: Zeitschriftenaufsatz
VL - 32
SP - 741
EP - 746
JO - ONKOLOGIE
JF - ONKOLOGIE
SN - 0378-584X
IS - 12
M1 - 12
ER -
